167 related articles for article (PubMed ID: 32656777)
21. A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.
Berenson J; Manges R; Badarinath S; Cartmell A; McIntyre K; Lyons R; Harb W; Mohamed H; Nourbakhsh A; Rifkin R
Am J Hematol; 2017 May; 92(5):460-466. PubMed ID: 28213943
[TBL] [Abstract][Full Text] [Related]
22. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Lonial S; Dimopoulos M; Palumbo A; White D; Grosicki S; Spicka I; Walter-Croneck A; Moreau P; Mateos MV; Magen H; Belch A; Reece D; Beksac M; Spencer A; Oakervee H; Orlowski RZ; Taniwaki M; Röllig C; Einsele H; Wu KL; Singhal A; San-Miguel J; Matsumoto M; Katz J; Bleickardt E; Poulart V; Anderson KC; Richardson P;
N Engl J Med; 2015 Aug; 373(7):621-31. PubMed ID: 26035255
[TBL] [Abstract][Full Text] [Related]
23. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
Salwender H; Bertsch U; Weisel K; Duerig J; Kunz C; Benner A; Blau IW; Raab MS; Hillengass J; Hose D; Huhn S; Hundemer M; Andrulis M; Jauch A; Seidel-Glaetzer A; Lindemann HW; Hensel M; Fronhoffs S; Martens U; Hansen T; Wattad M; Graeven U; Munder M; Fenk R; Haenel M; Scheid C; Goldschmidt H
BMC Cancer; 2019 May; 19(1):504. PubMed ID: 31138244
[TBL] [Abstract][Full Text] [Related]
24. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Lonial S; Vij R; Harousseau JL; Facon T; Moreau P; Mazumder A; Kaufman JL; Leleu X; Tsao LC; Westland C; Singhal AK; Jagannath S
J Clin Oncol; 2012 Jun; 30(16):1953-9. PubMed ID: 22547589
[TBL] [Abstract][Full Text] [Related]
25. Once Monthly Elotuzumab and Lenalidomide Plus Dexamethasone for Multiple Myeloma: A Multicenter Observation Study.
Suzuki K; Matsumoto M; Hiramatsu Y; Takezako N; Tamai Y; Suzuki K
Acta Haematol; 2023; 146(2):125-136. PubMed ID: 36538896
[TBL] [Abstract][Full Text] [Related]
26. Elotuzumab: First Global Approval.
Markham A
Drugs; 2016 Mar; 76(3):397-403. PubMed ID: 26809244
[TBL] [Abstract][Full Text] [Related]
27. Elotuzumab: Empiric analysis of dexamethasone administration schedule.
Kintzel PE
J Oncol Pharm Pract; 2024 Jan; 30(1):235-238. PubMed ID: 37876226
[TBL] [Abstract][Full Text] [Related]
28. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
Palumbo A; Sonneveld P
Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331
[TBL] [Abstract][Full Text] [Related]
29. Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study.
Regidor B; Swift R; Eades B; Emamy-Sadr M; Tarhini F; Spektor TM; Berenson JR
Ann Hematol; 2021 Apr; 100(4):1079-1085. PubMed ID: 33237342
[TBL] [Abstract][Full Text] [Related]
30. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial.
Dimopoulos MA; Lonial S; Betts KA; Chen C; Zichlin ML; Brun A; Signorovitch JE; Makenbaeva D; Mekan S; Sy O; Weisel K; Richardson PG
Cancer; 2018 Oct; 124(20):4032-4043. PubMed ID: 30204239
[TBL] [Abstract][Full Text] [Related]
31. A New Monoclonal Protein Detected in a Patient With Myeloma Undergoing Elotuzumab Therapy.
Tang F; Schmotzer C; Beck RC
JAMA Oncol; 2017 Dec; 3(12):1729-1730. PubMed ID: 28880973
[No Abstract] [Full Text] [Related]
32. Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.
Mateos MV; Granell M; Oriol A; Martinez-Lopez J; Blade J; Hernandez MT; Martín J; Gironella M; Lynch M; Bleickardt E; Paliwal P; Singhal A; San-Miguel J
Br J Haematol; 2016 Nov; 175(3):448-456. PubMed ID: 27434748
[TBL] [Abstract][Full Text] [Related]
33. Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy.
Danhof S; Strifler S; Hose D; Kortüm M; Bittrich M; Hefner J; Einsele H; Knop S; Schreder M
J Cancer Res Clin Oncol; 2019 Mar; 145(3):561-571. PubMed ID: 30519736
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of elotuzumab for the treatment of multiple myeloma.
Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Drug Saf; 2017 Feb; 16(2):237-245. PubMed ID: 28060563
[TBL] [Abstract][Full Text] [Related]
35. Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.
Jagannath S; Laubach J; Wong E; Stockerl-Goldstein K; Rosenbaum C; Dhodapkar M; Jou YM; Lynch M; Robbins M; Shelat S; Anderson KC; Richardson PG
Br J Haematol; 2018 Aug; 182(4):495-503. PubMed ID: 29808907
[TBL] [Abstract][Full Text] [Related]
36. Elotuzumab as a novel anti-myeloma immunotherapy.
Radhakrishnan SV; Bhardwaj N; Steinbach M; Weidner J; Luetkens T; Atanackovic D
Hum Vaccin Immunother; 2017 Aug; 13(8):1751-1757. PubMed ID: 28604269
[TBL] [Abstract][Full Text] [Related]
37. Elotuzumab-based maintenance therapy following autologous stem cell transplant in multiple myeloma deepens post-transplant responses.
Wang X; Vogt B; Shanahan L; Siddiqui AD; Subramonia-Iyer S; Khanani S; Bednarik JL; Mittal K; Ramanathan M; Gerber JM; Cerny J
Blood Cells Mol Dis; 2020 Nov; 85():102482. PubMed ID: 32745939
[TBL] [Abstract][Full Text] [Related]
38. Elotuzumab in the treatment of relapsed and refractory multiple myeloma.
Grosicki S; Bednarczyk M; Barchnicka A; Grosicka O
Future Oncol; 2021 May; 17(13):1581-1591. PubMed ID: 33478270
[TBL] [Abstract][Full Text] [Related]
39. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.
Jakubowiak AJ; Benson DM; Bensinger W; Siegel DS; Zimmerman TM; Mohrbacher A; Richardson PG; Afar DE; Singhal AK; Anderson KC
J Clin Oncol; 2012 Jun; 30(16):1960-5. PubMed ID: 22291084
[TBL] [Abstract][Full Text] [Related]
40. Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan.
Suzuki K; Ri M; Chou T; Sugiura I; Takezako N; Sunami K; Ishida T; Izumi T; Ozaki S; Shumiya Y; Ota K; Iida S
Cancer Sci; 2017 Mar; 108(3):461-468. PubMed ID: 28092421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
